FP7 logo euThe ESNATS project has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement n° HEALTH-F5-2008-201619

Embryonic Stem cell-based Novel Alternative Testing Strategies

Partners: F. Hoffmann-La Roche, Ltd.(ROCHE)

RocheHeadquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. For more than 100 years, Roche has been active in the discovery, development, manufacture and marketing of novel healthcare solutions. The products and services address prevention, diagnosis and treatment of diseases, thus enhancing well-being and quality of life. Roche is a world leader in diagnostics, the leading supplier of medicines for cancer and transplantation and a market leader in virology.

The department of toxicology within the pharmaceutical division is divided in specialised groups as e.g. the Reproductive Toxicology.

In ESNATS, ROCHE is a member of the Steering Committee and will, as such, provide advice and requirements on industry needs for assay development and specify reference compounds to be tested.

Key staff involved in the project

Nicole ClemannNicole Clemann, PhD, Senior Scientist, is a reproductive toxicologist with more than ten years experience in regulatory toxicology and in vitro models in reproductive toxicology. Her special interest is in screening models for developmental toxicology and early drug development. She is Council member of the European Teratology society and member of the Advisory Committee of "ALTEX".

Top ^